Endogena therapeutics receives us fda fast track designation for ea-2353 for the treatment of retinitis pigmentosa

San francisco, toronto and zÜrich, switzerland, feb. 06, 2023 (globe newswire) -- endogena therapeutics inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the us food and drug administration (fda) has designated the investigation of ea-2353 for the treatment of retinitis pigmentosa (rp) as a fast track development program. fast track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions.
EA Ratings Summary
EA Quant Ranking